November 11, 2026

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

Ref: Scrip Code: 543322

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Name: ALIVUS

Dear Sirs,

Sub: Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations")

We refer to our letter dated August 18, 2026 in relation to share purchase agreement to acquire 76% stake in IQGEN-X Pharma Private Limited ("IQGEN-X"). We wish to inform you that the Closing under the Share Purchase Agreement has been initiated; 7,36,096 equity shares representing 65.01% of the issued and paid-up equity share capital of IQGEN-X have been acquired by the Company and the remaining share capital of IQGEN-X will be acquired in due course. Accordingly, IQGEN-X Pharma Private Limited has become a subsidiary of the Company with effect from today.

This is for your information and records

Thanking You,

Your Sincerely,

For Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)

RUDALF JOSEPH CORRIEA
Digitally signed by RUDALF JOSEPH CORRIEA
Date: 2026.11.11 18:21:06 +05'30'

Rudalf Corriea
Company Secretary & Compliance Officer